Last reviewed · How we verify
Sugammadex Reversal
At a glance
| Generic name | Sugammadex Reversal |
|---|---|
| Sponsor | Hadassah Medical Organization |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 and 24 Months Old (PHASE4)
- The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery (PHASE4)
- Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease (PHASE4)
- Comparison of the Performances of the cTOFR and the mTOFR During Reversal of Deep Neuromuscular Blockade With Sugammadex
- Cardiac Output and Recovery Time (NA)
- NMBA Reversal and Postoperative Urinary Retention
- Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sugammadex Reversal CI brief — competitive landscape report
- Sugammadex Reversal updates RSS · CI watch RSS
- Hadassah Medical Organization portfolio CI